1. Discovery of ST2 Inhibitors: From Biomarker to Potential Drug Target in Graft-Versus- Host Disease 
Chao-Yie Yang, PhD, Jilu Zhang, PhD, Etienne Daguindau, MD, Zachary Bolten, Krishnapriya Chinnaswamy, MS, Jeanne A. Stuckey, PhD, Sophie Paczesny, MD, PhD 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S91-S93 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Integration of high throughput screening and computational analysis to identify ST2 inhibitors. The funnel outlines the step-wise procedures to select compounds starting from initial primary screening of compound libraries with increase of confidence.
Biology of Blood and Marrow Transplantation  , S91-S93DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
ST2 inhibitors in in vitro and In vivo GVHD models. A. CDS T cell proliferation measured by CFSE dilution and IFN - γ production in MLR with DMSO or ST2 inhibitors. B DMSO or ST2 inhibitors were administered IP from day-1 to day 8 after HCT to NGS mice transplanted with human T cells, n=7, *p<0.05. C. Systemic plasma ST2 and IFN - γ in DMSO or ST2 inhibitors treated group at days 7, 14 and 28 after HCT, n=5, *p<0.05.
Biology of Blood and Marrow Transplantation  , S91-S93DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
Ex vivo analysis of CD8T cells and regulator T cells at day 10 after HCT. DMSO or ST2 inhibitors were administered to mice transferred with human T cells via intra - peritoneal injection every day from day - 1 to day 8 after HCT Splenic T cells were collected for T - bet/Ki67, IFN - y and FoxP3 intracellular staining at day 10 after HCT.
Biology of Blood and Marrow Transplantation  , S91-S93DOI: ( /j.bbmt )
Copyright © Terms and Conditions